{"name":"Associazione Volontari Pazienti Oncologici","slug":"associazione-volontari-pazienti-oncologici","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"RT+CETUXIMAB","genericName":"RT+CETUXIMAB","slug":"rt-cetuximab","indication":"Head and neck cancer (squamous cell carcinoma)","status":"phase_3"},{"name":"RT+CDDP/5-FU","genericName":"RT+CDDP/5-FU","slug":"rt-cddp-5-fu","indication":"Metastatic colorectal cancer","status":"phase_3"}]}],"pipeline":[{"name":"RT+CETUXIMAB","genericName":"RT+CETUXIMAB","slug":"rt-cetuximab","phase":"phase_3","mechanism":"RT+CETUXIMAB combines radiation therapy with cetuximab, an EGFR-blocking monoclonal antibody, to inhibit tumor cell growth and enhance radiosensitivity.","indications":["Head and neck cancer (squamous cell carcinoma)","Locally advanced cancers amenable to radiotherapy"],"catalyst":""},{"name":"RT+CDDP/5-FU","genericName":"RT+CDDP/5-FU","slug":"rt-cddp-5-fu","phase":"phase_3","mechanism":"RT+CDDP/5-FU is a combination chemotherapy regimen that works by inhibiting DNA replication and interfering with DNA repair, ultimately leading to cell death.","indications":["Metastatic colorectal cancer","Metastatic gastric cancer"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":2},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}